INBX
HealthcareInhibrx Biosciences, Inc. · Biotechnology · $2B
What is Inhibrx Biosciences, Inc.?
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics for patients facing life-threatening conditions. Incorporated in 2024 and headquartered in La Jolla, California, the company is building a pipeline targeting rare cancers and solid tumors.
Inhibrx Biosciences advances novel biologic drug candidates through clinical trials, generating no commercial revenue at this stage. Its lead programs target specific cancer pathways using engineered antibody-based formats designed to activate immune responses or trigger tumor cell death. The company funds its operations through capital markets activity rather than product sales, which is typical for clinical-stage biotechs. Its focus is on unmet medical needs in oncology, including rare bone cancers and multiple solid tumor types.
Inhibrx Biosciences was incorporated in 2024 and is based in La Jolla, California.
- INBRX-109: tetravalent DR5-targeting candidate in Phase 2 for chondrosarcoma
- INBRX-106: hexavalent OX40-targeting candidate in Phase 2 for multiple solid tumors
- Engineered sdAb-based biologic platform for oncology therapeutics
Is INBX a Good Stock to Buy?
UQS Score rates INBX as Poor overall, reflecting the early-stage nature of its business and the significant uncertainties that come with a clinical-stage biotech.
The Growth pillar stands out as the relative bright spot in INBX's profile, acknowledging the potential trajectory of its clinical pipeline. The Risk pillar registers as Neutral, suggesting the company's risk profile is not extreme relative to its peer group — a notable characteristic for a pre-revenue biotech.
Both the Quality and Moat pillars are rated Weak, consistent with a company that has no commercial products and limited durable competitive advantages established to date. Valuation is rated Elevated, meaning the current market price appears to price in considerable optimism.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does INBX pay dividends?
Yes — Inhibrx Biosciences, Inc. pays a dividend.
Inhibrx Biosciences does pay a dividend, which is unusual for a clinical-stage biopharmaceutical company with no commercial revenue. Investors should review the company's investor relations page to understand the nature, source, and sustainability of these distributions, as the context differs significantly from dividend-paying mature businesses.
When does INBX report earnings?
Inhibrx Biosciences reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly results center on pipeline progress, cash runway, and operating expenses rather than revenue growth. Key updates typically include trial enrollment milestones and capital position disclosures.
For the most recent quarter's results and upcoming reporting dates, visit Inhibrx Biosciences' investor relations page directly.
INBX Price History
+307.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Inhibrx Biosciences, Inc.?
Based on Inhibrx Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
INBX Long-term Outlook
The fundamental outlook for INBX is driven almost entirely by clinical trial outcomes rather than near-term financial performance. The Good Growth pillar label reflects the potential value embedded in its Phase 2 programs, but this potential remains binary and event-driven. The Elevated Valuation pillar suggests the market is already pricing in meaningful pipeline success, which raises the stakes for upcoming data readouts. The Neutral Risk rating provides some reassurance that the company's risk profile is not at the extreme end of the clinical-stage spectrum.
Growth drivers
- Phase 2 clinical advancement of INBRX-109 in rare chondrosarcoma
- Broad solid tumor indications targeted by INBRX-106 across multiple cancer types
- Engineered biologic platform with potential for additional pipeline candidates
Key risks
- Clinical trial failure risk — no approved products or commercial revenue
- Elevated valuation leaves limited margin of safety if trial data disappoints
- Ongoing capital dependency typical of pre-revenue biotech companies
INBX vs Peers
Inhibrx Biosciences operates in a competitive clinical-stage oncology landscape alongside several similarly positioned biotechs.
Monte Rosa focuses on targeted protein degradation via molecular glue technology, a mechanistically distinct approach from Inhibrx's antibody-based platform.
Iovance pursues tumor-infiltrating lymphocyte cell therapies, representing a different immunotherapy modality compared to Inhibrx's engineered biologic candidates.
ArriVent concentrates on targeted therapies for thoracic cancers, with a narrower tumor-type focus than Inhibrx's broader solid tumor ambitions.
Frequently Asked Questions
What does Inhibrx Biosciences do?
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic therapeutics for patients with life-threatening conditions. Its pipeline focuses on engineered antibody-based drug candidates targeting cancer pathways, currently in Phase 2 trials for rare bone cancers and multiple solid tumor types.
Does INBX pay dividends?
Yes, Inhibrx Biosciences does pay a dividend. This is uncommon for a clinical-stage biotech with no commercial products. Investors should consult the company's investor relations page to understand the nature and sustainability of these distributions before drawing conclusions about income potential.
When does INBX report earnings?
Inhibrx Biosciences reports on a quarterly cadence, as is standard for US-listed companies. For exact reporting dates and the most recent results, check the company's official investor relations page, as our data source does not cover specific upcoming earnings dates.
Is INBX a good stock to buy?
UQS Score rates INBX as Poor overall, driven by Weak Quality and Moat pillars alongside an Elevated Valuation. The Growth pillar is the relative strength. Whether INBX fits a portfolio depends on individual risk tolerance and conviction in its clinical pipeline. View the full pillar breakdown on UQS Pro for deeper context.
Is INBX overvalued?
The UQS Valuation pillar for INBX is rated Elevated, indicating the current market price reflects considerable optimism about pipeline outcomes. For a pre-revenue clinical-stage company, valuation is inherently speculative and tied to binary clinical data events rather than current earnings power.
How does INBX compare to its competitors?
Inhibrx Biosciences competes with other clinical-stage oncology biotechs including Monte Rosa Therapeutics, Iovance Biotherapeutics, and ArriVent BioPharma. Each pursues distinct therapeutic modalities. INBX differentiates through its engineered sdAb-based biologic platform targeting DR5 and OX40 pathways across multiple cancer indications.
What is INBX's market cap bracket?
Inhibrx Biosciences is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, which is consistent with its clinical-stage development profile.
Who founded Inhibrx Biosciences?
Inhibrx Biosciences was incorporated in 2024. Founding and leadership details are publicly available through the company's official disclosures and investor relations materials, which provide the most accurate and current information on its executive team.
Is INBX a long-term quality investment?
As a long-term quality indicator, UQS rates INBX as Poor, reflecting weak fundamentals in Quality and Moat alongside an Elevated Valuation. Long-term quality investing typically favors companies with durable competitive advantages and consistent financial performance — characteristics not yet established for a clinical-stage biotech like INBX.
What is the main competitive advantage of Inhibrx Biosciences?
Inhibrx Biosciences' potential differentiation lies in its engineered biologic platform, which uses multivalent antibody formats designed to engage cancer targets more effectively than conventional approaches. However, the UQS Moat pillar is rated Weak, reflecting that durable competitive advantages are not yet established at this stage of development.
What sector does INBX belong to?
Inhibrx Biosciences operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. This segment is characterized by high risk, long development timelines, and the potential for significant value creation — or loss — depending on clinical trial outcomes.
Is INBX a growth stock or value stock?
Based on its UQS pillar profile, INBX leans toward growth — the Growth pillar is rated Good, reflecting pipeline potential. However, the Elevated Valuation pillar means investors are paying a premium for that growth potential, which is typical for clinical-stage biotechs with promising but unproven drug candidates.
Unlock Full INBX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for INBX
- ✓Access full financial metrics and trend data
- ✓Compare INBX against sector peers side by side
- ✓See Quality, Moat, and Valuation breakdowns in detail
- ✓Get the complete analyst-grade view for any ticker
Pro Analysis
INBX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 24.3 | 0.0 | 9.0 | 63.1 | 62.8 | 0.0 | +3.9 |
| May 8, 2026 | 20.4 | 0.0 | 9.0 | 63.1 | 36.9 | 0.0 | -2.0 |
| Apr 4, 2026 | 22.4 | 0.0 | 9.0 | 63.1 | 50.4 | 0.0 | 0.0 |
| Apr 2, 2026 | 22.4 | 0.0 | 9.0 | 63.1 | 50.5 | 0.0 | — |
INBX — Pillar Breakdown
Quality
— 0.0/100 (25%)Inhibrx Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 63.1/100 (20%)Inhibrx Biosciences, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 62.8/100 (15%)Inhibrx Biosciences, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Inhibrx Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Inhibrx Biosciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for INBX.
Score Composition
Financial Data
More Stock Analysis
How is the INBX UQS Score Calculated?
The UQS (Unified Quality Score) for Inhibrx Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Inhibrx Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Inhibrx Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.